<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2010</study_start_year><condition>Metastatic Colorectal Cancer</condition><condition>Colorectal cancer</condition><condition>Advanced Solid Tumors</condition><condition>Colorectal Neoplasms</condition><condition>Solid tumors</condition><disease>Metastatic Colorectal Cancer</disease><disease>Advanced Solid Tumors</disease><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><disease>Solid Tumors</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2097924</full_dataset_link><location>United States</location><study_start_month>8</study_start_month><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer</name><description>The primary objective is to determine the maximum tolerated dose/recommended phase II dose of the combination regimen of NK012 and 5-fluorouracil in patients with advanced solid tumors.</description><dates><creation>2010-08-15</creation></dates><accession>2097924</accession><cross_references><ClinicalTrials___gov>NCT01238939</ClinicalTrials___gov></cross_references></HashMap>